A rash while taking lamotrigine can indicate a serious reaction that requires stopping the medication and going to the emergency room. A psychiatrist explains the signs.
A patient with bipolar disorder, stably taking lamotrigine for three weeks, starts scratching a forearm. A discreet red mark appears, about the size of a coin. He thinks it is a new soap, an insect bite, tight clothing. He takes an antihistamine and goes to sleep.
Over the next thirty-six hours, that same skin can do something that may threaten his life.
This text is about a rare but real, recognizable scenario in which timely identification depends on one thing: the patient himself knowing that this mark means something. Lamotrigine is an excellent medication for bipolar disorder, affective disorders more broadly, and some forms of epilepsy. It is well tolerated by the majority of patients. But it carries a specific cutaneous risk that needs to be named clearly, because prescribing physicians do not always name it, and almost no patient reads the leaflet carefully enough to retain the information under stress.
The reaction that changes everything within hours
The reaction we worry about is not a common allergy. It is a systemic dermatological syndrome called Stevens-Johnson syndrome (SJS), with its more severe variant, toxic epidermal necrolysis (TEN). In both, the skin peels off in sheets, mucous membranes (mouth, eyes, genitals) become inflamed and ulcerate, and the picture can progress to multi-organ failure. Mortality in TEN, even with proper treatment in specialized units, reaches thirty percent in some case series.
It is not common. Incidence with lamotrigine is estimated between one in a thousand and one in five thousand treated patients. But when it happens, it is a race against the clock. And the difference between a bad outcome and a catastrophic one is often measured in hours — not days.
The early signs that demand maximum attention
The severe reaction almost never begins as a severe reaction. It begins as something banal: an isolated pink mark, a small blister, an itch that looks like dermatitis. The sign that this particular mark is different from the others appears shortly afterwards — and it is the combination of factors that raises the alarm:
Marks appearing at more than one site on the body at the same time, especially in areas not exposed to sun. Mucosal involvement — red, photophobic eyes, cracked lips or small blisters, pain on urination without infection, a sore throat worse than an ordinary cold would explain. Systemic symptoms — persistent low-grade fever, malaise, a strong flu-like feeling that does not match the season. Speed of progression — the mark that was small yesterday is larger today, or new ones have appeared.
A single one of these signs in isolation, in a patient on lamotrigine, already justifies an urgent conversation with the prescribing psychiatrist. The combination of two or more, especially with mucosal involvement or fever, is reason to go to the emergency department the same day — not tomorrow, not at the next scheduled visit.
Why lamotrigine in particular
Several medications can cause Stevens-Johnson syndrome. Antibiotics, anti-inflammatories, classical anticonvulsants. Lamotrigine appears on that list for a specific biochemical reason: it is metabolized through pathways which, in some patients with genetic predisposition, generate intermediates capable of triggering an immune cascade directed against keratinocytes — the most superficial cells of the skin. These keratinocytes die en masse, the skin loses adhesion, and the process becomes systemic.
It is not possible to predict with certainty who will react. Genetic markers exist (HLA-B*15:02, more frequent in Asian populations) that increase the risk, but the test is not routine in Brazil and does not eliminate the risk for those who do not carry these markers. What can be identified are modifiable factors — and that is what the next section is about.
The risk window where everything happens
The severe reaction to lamotrigine follows a temporal pattern worth knowing: it almost always appears in the first eight weeks of use. After that, the risk drops sharply and continues to decrease over time. A patient who has taken the medication for two years without any cutaneous incident has essentially zero chance of developing SJS now.
This critical window is precisely why the worldwide introduction protocol for lamotrigine is slow — low doses in the first week, gradual increases over several weeks. This is not excess caution. It is the only modifiable factor that reduces the risk: the slower the titration, the lower the probability of severe reaction.
A patient who receives a prescription with rapid escalation (whether due to clinical urgency or prescribing error) is at significantly higher risk. If you have received such a prescription, it is worth discussing this with the prescribing physician — not to judge the decision, which is sometimes justified, but so that cutaneous monitoring is even more attentive.
What to do the moment the mark appears
Here the rule is clear, without middle ground:
Minimal suspicion of a cutaneous reaction while taking lamotrigine — stop the medication immediately and go to the emergency department.
Do not wait to talk to the psychiatrist. Do not take an antihistamine and observe. Do not go back to the previous dose “just to be safe.” Stop. Go. Take the medication box with you so the ER physician can see the substance and start date.
The reason for urgency is technical: if the reaction is in fact the beginning of SJS, every hour matters. Early hospital support (hydration, care of skin and mucous membranes, ICU support if needed) reduces mortality. A twenty-four-hour delay can be the difference between discharge in five days and a prolonged hospitalization with sequelae.
If the reaction turns out to be benign (which is statistically the most likely scenario), the ER physician confirms this, you return to the assisting psychiatrist, and the decision about continuing or not continuing lamotrigine is made calmly. Nothing lost by acting quickly. Much gained, if by any chance it was the severe scenario.
Factors that multiply the risk
Some points deserve mention because they increase the likelihood of severe reaction and are recognizable:
Concomitant use of valproate. This combination (frequent in bipolar treatment) reduces the metabolism of lamotrigine and effectively raises its blood concentrations. Titration in this context needs to be even slower than usual. If you are taking both, check that your psychiatrist has made the appropriate reduction in the lamotrigine dose.
Re-exposure after a previous reaction. A patient who had any cutaneous reaction to lamotrigine in the past and returns to taking the medication is at much higher risk of severe reaction this time. Reintroduction in someone who had a previous allergic cutaneous reaction is only done in a controlled setting, and even then it is a decision made with rigorous clinical judgment.
Pediatric age. Children under sixteen have proportionally higher risk. This is not a reason to avoid lamotrigine in a child when indicated, but it requires even more vigilant cutaneous follow-up.
Reintroduction: a chapter of its own
A patient who had any suspicious reaction to lamotrigine and stopped the medication has a legitimate question: can I resume it later?
The answer is not simple and is not to be resolved alone. Ever. There are cases in which reintroduction is possible with controlled desensitization (extremely low dose, even slower increases, intensive clinical monitoring). There are cases in which it is not. The decision requires evaluation of the original episode (was it really an allergic reaction or something else?), the time elapsed, the available alternative, and the individual risk profile of the patient.
This kind of decision is the opposite of “I will try again on my own because I feel fine.” It is one of the situations in which psychiatric supervision is literally irreplaceable.
What the patient needs to retain from this text
One thing only, kept in mind for as long as you take lamotrigine: a new mark on the skin, especially in the first eight weeks of use, is reason to stop the medication and go to the emergency department the same day. The vast majority of the time it will be something banal. In the rare occasions when it is not, that decision saves the skin — and occasionally saves the life.
Lamotrigine is a good medication. Long-term treatment with it is safe for the majority of patients. What this text asks is only for specific attention to a specific sign during a specific period. Nothing more than that — and nothing less.
Related reading
- It is not just the way he is
- The treatment for depression that made everything worse
- He stopped taking it because he was finally well
Taking lamotrigine and unsure about the warning signs?
Book your appointment here
In-person appointments in Brasília (Asa Sul) or by teleconsultation anywhere in Brazil.
Dr. Leonardo Sodré is a psychiatrist and psychotherapist in Brasília, Brazil (CRM-DF 14.206 · RQE 14.761). He holds a PhD in Psychiatry from UFRGS and teaches at the University of Brasília School of Medicine. This content is informative and educational and does not replace individual assessment, diagnosis or treatment.